ChatGPT is an artificial intelligence (AI) chatbot that creates conversational dialogue with the user. 1 It has been used in clinical care and medical education. 2 Its potential role in diabetes education for patients has been explored, but safety concerns have been raised. 3,4 There has been much interest in how AI can have a role in Travel Medicine in teaching, providing more personalized advice, and aid in the pre-travel consultation. 5,6
Objectives Specific to sexual health, individuals in need of information may be adolescents who have limited ability to formally access healthcare. These digital natives may turn to ChatGPT to address their concerns on sexually transmitted infections (STI). We sought to evaluate the veracity of ChatGPT’s responses to commonly asked questions on STIs. Methods We instructed ChatGPT (GPT 3.5) to answer STI questions from three domains, namely, (1) general risk factors for STIs, (2) access to care and diagnosis of STIs and (3) management of STIs and postexposure prophylaxis. The responses were recorded and checked against the US Centers for Disease Control and Prevention STI Treatment Guidelines 2021. Results Overall, the responses were concise and accurate. In terms of prevention, ChatGPT could also recommend measures like safe sex practices and human papillomavirus vaccination. However, it failed to recommend HIV pre-exposure prophylaxis. When an individual expressed a symptom that could potentially represent STI (eg, dyspareunia) ChatGPT appropriately provided reassurance that other possibilities exist, but advocated for testing. In terms of treatment, ChatGPT consistently communicated the importance of partner testing and follow-up testing, but at times, failed to highlight the importance of testing for other STIs. Overall, the advice given was not tailored to the specific individual’s circumstances. Conclusions ChatGPT can provide helpful information regarding STIs, but the advice lacks specificity and requires a human physician to fine-tune. Its ubiquity may make it a useful adjunct to sexual health clinics, to improve knowledge and access to care.
26 April 2024 in Journal of Infection and Public Health
Pneumocystis jirovecii pneumonia (PCP) is associated with significant mortality amongst patients without underlying human immunodeficiency virus infection (HIV). We sought to develop a risk score to predict mortality in this population. We reviewed patients with a presumed or confirmed PCP and a negative HIV test from 2006-2023. We constructed a multivariable model to identify parameters independently associated with mortality and the adjusted odds ratios were converted to weights to derive a risk score. Subsequently, we compared the performance of our score to the CURB-65 score by means of area under receiver operating characteristic curve (AUC). In total, we examined 93 patients with PCP without HIV. Mortality was 31.2%. Risk factors for mortality included older age, male sex and high serum lactate dehydrogenase levels (LDH) and C-reactive protein levels. A risk score was derived comprising age> 65 years (2 points), male sex (2 points) and LDH> 770 U/L (3 points). Our risk score (AUC 0.71, 95%CI 0.60-0.82) performed better than the CURB-65 score (AUC 0.53, 95%CI 0.41-0.66). A low-risk score of 0-1 had excellent negative predictive value for mortality (97.5%). In conclusion, a risk score comprising age, sex and LDH can predict mortality in PCP without underlying HIV and help with prognostication.
We designed and implemented an interactive artificial intelligence tool based on ChatGPT to complement the pre-travel consultation in a specialist tertiary centre that cares for a range of travellers including those who have undergone solid organ or bone marrow transplantation, as well as persons living with HIV.
14 May 2025 in Journal of Infection and Public Health
Stenotrophomonas maltophilia is an important nosocomial pathogen. Bacteraemia is associated with significant morbidity, despite antibiotic therapy. Optimal treatment strategies for Stenotrophomonas maltophilia bacteraemia remain ill-defined. Thus, we retrospectively examined the clinical presentation, microbiological characteristics, treatment options to identify risk factors for mortality. We performed a retrospective single-centre analysis of Stenotrophomonas maltophilia bacteraemia from 1 Jan 2012-30 Jun 2024. Data on the clinical presentation, source of infection, microbiological characteristics, treatment strategies and clinical outcomes were tabulated. Risk factors for in-hospital all-cause mortality were identified by appropriate univariate and multivariable analyses. There were 197 bacteraemia episodes. In-hospital mortality was 41.6 % (n = 82), and did not change significantly over the years. Patients who died were more likely to have prior carbapenem exposure (81.7 % vs 53.0 %, p < 0.001), presentation in an intensive care (ICU) setting (73.2 % vs 15.7 %, p < 0.001), and had a longer duration of fever (8.5 ± 2.5 vs 3.0 ± 3.8 days, p < 0.001). Microbiological isolation from additional sites other than the blood (e.g. sputum culture positivity) also correlated with mortality (39.0 % vs 7.8 %, p < 0.001). Over time, proportion of isolates resistant to fluoroquinolones increased. An initial antimicrobial choice containing trimethoprim-sulfamethoxazole appeared to be more likely to be associated with survival. Only 13 patients (6.6 %) received dual antibiotics initially, so it was unclear if this was associated with better outcomes. On multivariable analysis, ICU onset, elevated C-reactive protein, longer duration of fever and an absence of intervention for source control remained independently associated with mortality. Source control of infection may be critical in improving survival in Stenotrophomonas maltophilia bacteraemia. Future prospective studies should validate important risk factors for mortality and define optimal antimicrobial treatment strategies.
Background: Vaccines have eradicated deadly diseases, yet vaccine hesitancy persists, leading to reduced uptake. Some individuals, mistrustful of healthcare providers, may turn to tools like ChatGPT for information. We evaluated ChatGPT’s responses to common vaccine hesitancy questions. Methods: Infectious disease physicians compiled 15 frequently encountered questions relating to vaccine hesitancy, focusing on concerns about efficacy, adverse effects, and cultural or religious issues, and submitted them to ChatGPT on 18 October 2023. Two independent physicians assessed the responses for factual accuracy and alignment with recommendations from the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP). Results: A representative selection of responses is shown. ChatGPT consistently provided fact-based, reassuring responses. For instance, it accurately addressed the benefits of male HPV vaccination; however, it failed to consider ACIP’s age-specific recommendations and individual sexual health factors. While correcting mRNA vaccine misconceptions, it did not mention the availability of non-mRNA COVID-19 vaccines. It also lacked depth in discussing religious objections, deferring users to faith leaders and providers. Conclusions: ChatGPT provides generally accurate information and may be a useful adjunct in addressing vaccine hesitancy. With refinement, it could complement public health efforts to improve vaccine confidence and counter misinformation.